Tacrolimus as a primary immunosuppressive therapy in cadaveric renal transplantation: five years' experience at a single center.
Schneeberger
H
H
Division of Transplant Surgery, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany.
Zanker
B
B
Hillebrand
G
G
Illner
W D
WD
Rothenpieler
U
U
Land
W
W
D000328:Adult; D000368:Aged; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002102:Cadaver; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology / Q000628:therapy; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors; D014019:Tissue Donors
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016559:Tacrolimus